Clinical trial
Risk of Hepatitis C Virus Reinfection in Hemodialysis Patients With Chronic Hepatitis C Achieving Sustained Virologic Response Following Antiviral Therapy
NCT04732832 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Risk of Hepatitis C Virus Reinfection in Hemodialysis Patients With Chronic Hepatitis C Achieving Sustained Virologic Response Following Antiviral Therapy
- Lead sponsor
- National Taiwan University Hospital
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- February 1, 2021
- Completion date
- March 31, 2024
- Enrollment
- 350 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
hemodialysis complication, hepatitis c virus infection, hepatitis c virus infection, response to therapy of